PHK
RARE icon

Point72 Hong Kong’s Ultragenyx Pharmaceutical RARE Stock Holding History

Point72 Hong Kong’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$293K Sell
9,729
-7,592
-44% -$228K 0.01% 292
2025
Q2 		$630K Sell
17,321
-15,419
-47% -$556K 0.04% 235
2025
Q1 		$1.19M Buy
32,740
+5,341
+19% +$222K 0.08% 189
2024
Q4 		$1.15M Buy
27,399
+17,379
+173% +$862K 0.07% 177
2024
Q3 		$557K Buy
+10,020
New +$510K 0.04% 235
2024
Q2 		– Sell
-27,004
Closed -$1.26M – 677
2024
Q1 		$1.26M Buy
+27,004
New +$1.27M 0.06% 246
2022
Q4 		– Sell
-15,766
Closed -$653K – 1332
2022
Q3 		$653K Buy
+15,766
New +$810K 0.02% 656
2022
Q1 		– Sell
-21
Closed -$2K – 2249
2021
Q4 		$2K Sell
21
-7,870
-100% -$640K ﹤0.01% 1780
2021
Q3 		$712K Sell
7,891
-2,209
-22% -$200K 0.02% 842
2021
Q2 		$963K Buy
+10,100
New +$1.05M 0.03% 728
2020
Q4 		– Sell
-688
Closed -$57K – 1998
2020
Q3 		$57K Buy
+688
New +$57K 0.01% 659
2019
Q4 		– Sell
-20
Closed -$1K – 1406
2019
Q3 		$1K Buy
+20
New +$1.09K ﹤0.01% 917
2019
Q1 		– Sell
-23
Closed -$1K – 1234
2018
Q4 		$1K Sell
23
-43
-65% -$2.35K ﹤0.01% 811
2018
Q3 		$5K Buy
+66
New +$5.37K ﹤0.01% 711
2017
Q3 		– Sell
-108
Closed -$7K – 1014
2017
Q2 		$7K Buy
108
+86
+391% +$5.18K 0.01% 516
2017
Q1 		$1K Buy
+22
New +$1.68K ﹤0.01% 680

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Point72 Hong Kong's RARE Position: Q3 2025 in Review

Point72 Hong Kong reduced its Ultragenyx Pharmaceutical (RARE) stake by 44% in Q3 2025, selling an estimated $228K and leaving 9,729 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #292.

Point72 Hong Kong first reported a position in RARE in Q1 2017 and has held it in 16 quarters since. The position peaked at $1.26M in Q1 2024. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Point72 Hong Kong held 9,729 shares of Ultragenyx Pharmaceutical worth $293K as of Q3 2025.
  • Point72 Hong Kong sold 7,592 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $228K.
  • Ultragenyx Pharmaceutical made up 0.01% of Point72 Hong Kong's portfolio in Q3 2025, its #292 holding.
  • Point72 Hong Kong first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 16 quarters since.
  • Point72 Hong Kong's Ultragenyx Pharmaceutical position peaked at $1.26M in Q1 2024.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.